210 related articles for article (PubMed ID: 33303254)
1. Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges.
Arunogiri S; Lintzeris N
J Subst Abuse Treat; 2021 May; 124():108221. PubMed ID: 33303254
[TBL] [Abstract][Full Text] [Related]
2. Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia.
Roberts J; White B; Attalla D; Ward S; Dunlop AJ
Addiction; 2021 Feb; 116(2):426-427. PubMed ID: 32888226
[No Abstract] [Full Text] [Related]
3. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
[TBL] [Abstract][Full Text] [Related]
4. Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
Soyka M
Pharmacopsychiatry; 2021 Jan; 54(1):18-22. PubMed ID: 33212514
[TBL] [Abstract][Full Text] [Related]
5. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
Larance B; Degenhardt L; Grebely J; Nielsen S; Bruno R; Dietze P; Lancaster K; Larney S; Santo T; Shanahan M; Memedovic S; Ali R; Farrell M
Addiction; 2020 Jul; 115(7):1295-1305. PubMed ID: 31860767
[TBL] [Abstract][Full Text] [Related]
6. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
[TBL] [Abstract][Full Text] [Related]
7. Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021.
Vidyasagar N; Bunting SR; Arora VM; Ari M
JAMA; 2024 Feb; 331(6):524-526. PubMed ID: 38236586
[TBL] [Abstract][Full Text] [Related]
8. The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019-2022: longitudinal sales data analysis.
Lintzeris N; Hayes V; Dunlop AJ
Med J Aust; 2024 Apr; 220(6):339-340. PubMed ID: 38438113
[No Abstract] [Full Text] [Related]
9. Diagnosis and Treatment of Opioid Use Disorder in 2020.
Wakeman SE
JAMA; 2020 May; 323(20):2082-2083. PubMed ID: 32329798
[No Abstract] [Full Text] [Related]
10. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
Sigmon SC; Bigelow GE
Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
[No Abstract] [Full Text] [Related]
11. Extended-Release Buprenorphine Receives FDA Green Light.
Harris E
JAMA; 2023 Jun; 329(24):2119. PubMed ID: 37285164
[No Abstract] [Full Text] [Related]
12. Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island.
Clark SA; Davis C; Wightman RS; Wunsch C; Keeler LAJ; Reddy N; Samuels EA
J Subst Abuse Treat; 2021 May; 124():108283. PubMed ID: 33771282
[TBL] [Abstract][Full Text] [Related]
13. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine Treatment for Opioid Use Disorder: An Overview.
Shulman M; Wai JM; Nunes EV
CNS Drugs; 2019 Jun; 33(6):567-580. PubMed ID: 31062259
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous Buprenorphine for a Patient With a History of Misusing an Indwelling Catheter: A Case Report.
Farahmand P; Kim J; Twark C; Suzuki J
Psychosomatics; 2020; 61(3):284-287. PubMed ID: 31629483
[No Abstract] [Full Text] [Related]
16. Initial experience with subcutaneous depot buprenorphine in a medically supervised injecting facility.
Weeks A; Cogger S; Clark N
Drug Alcohol Rev; 2021 Nov; 40(7):1354-1355. PubMed ID: 33821545
[No Abstract] [Full Text] [Related]
17. [New slow-release buprenorphine formulations for optimization of opioid substitution].
Soyka M; Pogarell O
Nervenarzt; 2019 Sep; 90(9):932-937. PubMed ID: 31399813
[TBL] [Abstract][Full Text] [Related]
18. Acute Pain Management for a Tibial Plateau Fracture Shortly After a Buprenorphine XR Depot Injection: A Case Report.
Sivanathan L; Logan E; Popovski K; Goel A; Hauck T; Ladha KS
J Addict Med; 2022 Sep-Oct 01; 16(5):599-601. PubMed ID: 35093985
[TBL] [Abstract][Full Text] [Related]
19. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.
Neale J; Tompkins CNE; Strang J
Drug Alcohol Rev; 2019 Jul; 38(5):510-518. PubMed ID: 31131514
[TBL] [Abstract][Full Text] [Related]
20. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.
Dunlop AJ; White B; Roberts J; Cretikos M; Attalla D; Ling R; Searles A; Mackson J; Doyle MF; McEntyre E; Attia J; Oldmeadow C; Howard MV; Murrell T; Haber PS; Lintzeris N
Addiction; 2022 Feb; 117(2):382-391. PubMed ID: 34184798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
